Trending
Merck & Co. (MRK) lifts full-year 2026 sales outlook, raises EPS midpoint
Merck & Co. has raised its full-year 2026 sales guidance to a range of $65.8 billion to $67.0 billion, simultaneously lifting its non-GAAP earnings per share midpoint to $5.10. The updated outlook follows the pharmaceutical company's first-quarter 2026 results, which reported sal
Read story →
Eli Lilly (LLY) hit with $194 million fraud damages after Supreme Court appeal denied
Eli Lilly and Company faces approximately $194 million in fraud damages after the U.S. Supreme Court declined on 18 May 2026 to hear its appeal in a Medicaid wh
Read story →
Vertex Pharmaceuticals (VRTX) sees continued reaction after Q1 revenue miss
Continued market reaction to Vertex Pharmaceuticals' Q1 2026 earnings report drove its shares down 3.2% on 5 May 2026, closing the session at $416.02. The decli
Read story →
Waters Corporation (WAT) Q1 earnings significantly surpass analyst expectations
Waters Corporation (WAT) shares closed up 11.9% at $337.90 on May 5, 2026, after the company reported first-quarter earnings that significantly surpassed analys
Read story →
Revvity (RVTY) shares rise after stronger-than-expected Q1 earnings beat
Revvity reported stronger-than-expected first quarter results, driving its shares 3.6% higher to close at $89.61 on 5 May. The United States-based life sciences
Read story →
AbbVie (ABBV) management to host fireside chat at BofA Healthcare Conference
AbbVie is scheduled to participate in the Bank of America Securities Healthcare Conference on May 13, 2026. Management will host a fireside chat at 1:20 p.m. Ce
Read story →
Merck (MRK) reverses pressure with strong Q1 earnings and pipeline developments
Merck & Co. shares rose 4.4% to $113.95 on Tuesday, 12 May 2026, after the company reported strong first-quarter earnings and outlined significant pipeline deve
Read story →
ResMed (RMD) stock declines after CEO Michael Farrell's insider share sale
ResMed (RMD) shares are trading down 4.1% today, with the medical device company's stock at $204.97. This movement follows insider selling by Chairman and Chief
Read story →
AbbVie (ABBV) management to present at Bank of America Healthcare Conference
AbbVie is scheduled to participate in the Bank of America Securities Healthcare Conference on May 13, 2026, where management will present. The United States-bas
Read story →
Stryker (SYK) misses first-quarter earnings expectations
Stryker Corporation shares are down 3.1% today, trading at $305.30, from yesterday's close of $315.13. The medical technology firm reported first-quarter earnin
Read story →
Merck (MRK) finalises $6.7 billion Terns Pharmaceuticals acquisition, bolsters pipeline
Merck & Co. finalised its $6.7 billion cash acquisition of Terns Pharmaceuticals on Tuesday, May 5, 2026. The transaction, which expands Merck's pharmaceutical
Read story →
Amgen (AMGN) reports strong Q1 earnings, surpassing analyst estimates
Amgen's shares saw significant movement on April 30, 2026, after the biotechnology company reported first-quarter earnings that surpassed analyst estimates. On
Read story →
Moderna (MRNA) flu vaccine mRNA-1010 shows positive Phase 3 data
Moderna shares closed up 4.3% on 30 April 2026, ending the session at $47.70. The move followed positive Phase 3 data for the company's mRNA-1010 trivalent flu
Read story →
Cardinal Health (CAH) reports revenue miss, significant profit reduction in Q3
Cardinal Health shares declined 6.0% to close at $190.51 on April 30, following its third-quarter fiscal 2026 earnings report which revealed a revenue miss and
Read story →
Merck (MRK) clears HSR regulatory hurdle for Terns Pharmaceuticals acquisition
Merck & Co. today announced the expiration of the Hart-Scott-Rodino (HSR) waiting period for its acquisition of Terns Pharmaceuticals, effectively clearing a si
Read story →
Rothschild & Co Redburn lowers price target on Cooper Companies (COO)
Rothschild & Co Redburn lowered its price target on Cooper Companies, contributing to a 3.2% decline in the stock on April 29, 2026. Shares of the large medical
Read story →
Dexcom (DXCM) Q3 earnings spark profitability concerns and cautious 2026 outlook
Dexcom closed at $57.45, down 3.2%, as investor concerns linger over the company's cautious 2026 guidance and deteriorating profitability. The decline extends
Read story →
Centene (CNC) Q1 earnings beat continues to drive strong investor sentiment
Centene Corporation (CNC) shares are extending gains today, trading up 7.4% at $53.22. The move follows the company's Q1 2026 earnings beat, reported on April 2
Read story →
Universal Health Services (UHS) beats Q1 earnings, expands acquisition firepower
Universal Health Services beat first-quarter earnings expectations and expanded its financial firepower for acquisitions. The healthcare operator reported EPS o
Read story →
Idexx Laboratories (IDXX) falls on analyst cuts, leadership changes
Idexx Laboratories shares fell today following analyst price target reductions and significant executive leadership changes. The veterinary diagnostics firm is
Read story →